nanotechnology rnai therapy rondel sirna drug delivery
nanobiotechnology arrowhead research calaa-01
clinical trial nano rondel sirna cancer rnai nanoparticles
Calando Pharmaceuticals
Calando's RONDEL delivery system extends the reach of RNAi therapy by answering the new field’s most pressing need — an effective and safe systemic delivery method.
CALAA-01, a formulation targeting cancer, combines Calando's proprietary drug delivery system, RONDEL, with an siRNA developed by Calando. CALAA-01 is currently undergoing a Phase 1 clinical trial at UCLA Medical Center in Los Angeles, California and START in San Antonio, Texas.
RNAi Overview
RNA interference (RNAi) is a naturally occurring mechanism that inhibits gene expression in a highly selective, sequence specific way. Since its discovery little more than a decade ago, the potential of this mechanism to revolutionize medicine has sparked excitement in both the biotech and pharmaceutical industries. As a result of considerable investment, RNAi based therapeutics are entering the clinic with promising new treatments for diseases like macular degeneration, RSV and cancer.
Combined with a safe and effective delivery method, RNAi-based treatments for life threatening and fatal diseases like cancer, AIDS, hepatitis C, Huntington’s disease and others become possible.
News
- 04/27/11
Arrowhead Research Announces RNAi Leader John J. Rossi, PH.D. to Join Calando Scientific Advisory Board Read
- 01/18/11
Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals Read
- 09/29/10
Arrowhead Ceo Provides Update on Company Strategy and Milestone Achievements Read
- 09/23/10
Arrowhead Increases Ownership in RNAi Subsidiary Calando Pharmaceuticals, Inc. Read - Read More
Calando Pharmaceuticals, Inc. is a majority-owned subsidiary of Arrowhead Research Corporation.